Drug · DIN 02454130
BLEXTEN
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since May 30, 2019; first marketed December 2, 2016.
- Drug Identification Number (DIN)
- 02454130
- Company (DIN owner)
- Aralez Pharmaceuticals Canada Inc.Toronto, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Bilastine R06AX29
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| BILASTINE | 20 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- December 14, 2018: NOC 21631New Drug Submission (NDS) · Administrative: Change in Product Ownership
- April 21, 2016: NOC 18011New Drug Submission (NDS)
Other DINs named BLEXTEN
- DIN 02519011 · Marketed
- DIN 02519038 · Marketed
- DIN 02561514 · Approved